Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Urinary Bladder Neoplasms 2Prostatic Neoplasms 2Carcinoma, Transitional Cell 2Urologic Neoplasms 1Squamous Cell Lung Cancer 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Docetaxel 137Prednisone 120Abiraterone Acetate 91Leuprolide 86enzalutamide 84Radiotherapy 59bicalutamide 56Magnetic Resonance Spectroscopy 54Goserelin 54Androgen Antagonists 51acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 47apalutamide 44abiraterone 34Radiosurgery 31Specimen Handling 30gallium 68 PSMA-11 29Gonadotropin-Releasing Hormone 29cabazitaxel 28Carboplatin 27darolutamide 26Estramustine 24luprolide acetate gel depot 23relugolix 22Metformin 22Triptorelin Pamoate 20sipuleucel-T 19radium Ra 223 dichloride 19Radiation 19pembrolizumab 18deltacortene 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Prostatic Neoplasms × apatorsen × Clear all
NCT01681433 2022-07-11

OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone

Hoosier Cancer Research Network

Phase 2 Terminated
72 enrolled 14 charts
Genitourinary

Prostatic Neoplasms

NCT01120470 2019-02-15

OGX-427 in Castration Resistant Prostate Cancer Patients

British Columbia Cancer Agency

Phase 2 Completed
74 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡